Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection

Monoclonal antibodies emerge as a new treatment option for patients with multiple myeloma, significantly broadening our therapeutic landscape in this disease. CD38 is a valuable target in the treatment of multiple myeloma since this antigen is over-expressed on malignant plasma cells.[1][1],[2][2]